Abstract: Provided are a protein conjugate in which a physiologically active polypeptide is linked to a biocompatible material via a non-peptidyl polymer-coupled fatty acid derivative compound serving as a linker, exhibiting an increased duration of physiological activity compared to natural forms and a preparation method therefor. Since an increase in serum half-life of the physiologically active polypeptide of the protein conjugate, in which the biocompatible material, the non-peptidyl polymer-coupled fatty acid derivative compound, and the physiologically active polypeptide are linked, is proved, the protein conjugate may be widely used in the field of protein drugs.

Abstract: An isolated or a synthetic targeting peptide comprising an amino acid sequence that is at least 90% identical to SEQ ID NO: 8 is disclosed. The targeting peptide may be conjugated to a component selected from the group consisting of polymeric micelles, lipoprotein-based drug carriers, nanoparticle drug carriers, a chemotherapeutic agent, a micelle, a liposome, dendrimers, a polymer, a lipid, an oligonucleotide, a peptide, a polypeptide, a protein, a prostate cancer cell, a stem cell, and an imaging agent. Also disclosed are a kit for imaging and detecting the presence of prostate cancer cells in vivo or in vitro, and a composition for treating prostate cancer, inhibiting prostate cancer cell growth, inducing prostate cancer cell cytotoxicity, and/or increasing the survival rate in a prostate cancer patient.

Abstract: The present invention provides peptide conjugates capable of translocating across the cytoplasmic membrane of a mammalian cell and inhibiting the Notch signalling pathway. Peptide conjugates, compositions and methods of the invention are useful for targeting chemo-resistant cancer stem cells.

Abstract: The present invention provides antibody drug conjugates, wherein an antibody or antibody fragment that specifically binds to human cKIT is linked to a drug moiety, optionally through a linker. The present invention further provides pharmaceutical compositions comprising the antibody drug conjugates; and methods of making and using such pharmaceutical compositions for ablating hematopoietic stem cells in a patient in need thereof.

Abstract: The invention provides compositions containing cargo molecules attached to elements that improve the function of the cargo molecules in the body of a subject. The compositions are useful for therapeutic and diagnostic purposes. Furthermore, the invention outlines ways in which these compositions can be produced; the core molecule can be functionalized, via bioorthogonal click chemistry, in such a way as to impart modular characteristics. This functionalization simultaneously allows for loading of biologically relevant cargo and provides stabilization to the overall structure of the molecule.

Abstract: A composition of matter and method of treating HIV with mesenchymal stem cells (MSC) is disclosed. Specifically, MSCs are transduced with vectors incorporating an anti-viral fusion inhibitor, such as a C46-derived peptide or neutralizing antibody. The transduced MSCs are capable of expression the inhibitor and preventing HIV virus-cell fusion.

Abstract: Sequences of novel adeno-associated virus capsids and vectors and host cells containing these sequences are provided. Also described are methods of using such host cells and vectors in production of rAAV particles. AAV-mediated delivery of therapeutic and immunogenic genes using the vectors of the invention is also provided.

Abstract: Sequences of novel adeno-associated virus capsids and vectors and host cells containing these sequences are provided. Also described are methods of using such host cells and vectors in production of rAAV particles. AAV-mediated delivery of therapeutic and immunogenic genes using the vectors of the invention is also provided.

Abstract: Disclosed herein is a recombinant nucleic acid, comprising: a mitochondrial targeting sequence; a mitochondrial protein coding sequence, wherein said mitochondrial protein coding sequence encodes a polypeptide comprising a mitochondrial protein; and a 3?UTR nucleic acid sequence. Also disclosed is a pharmaceutical composition comprising the recombinant nucleic acid and a method of treating Leber's hereditary optic neuropathy (LHON) using the pharmaceutical composition.

Abstract: The present disclosure provides codon optimized nucleotide sequences encoding human REP1, vectors, and host cells comprising codon optimized REP1 sequences, and methods of treating retinal disorders such as choroideremia comprising administering to the subject a codon optimized sequence encoding human REP1.

Abstract: The present invention is directed to a method for differentiating between ASD phenotype 1, phenotype 2 and other ASD patients, wherein the method comprises: administering an Nrf2-activator to a subject, and identifying the subject as an ASD phenotype 1 patient if the subject shows a negative response, as a phenotype 2 patient if he shows a positive response and as another ASD patient if he does not show a positive nor a negative response, wherein the subject is a patient previously diagnosed with idiopathic ASD or a subject displaying clinical signs of ASD.

Abstract: Imaging based detection of changes in extracellular neurotransmitter concentration in living tissue is achieved using novel nanotube-based sensors. The sensors are functionalized, neurocompatible single-walled carbon nanotubes (SWNT) comprising an adsorbed neurotransmitter analyte selective polynucleotide.

Abstract: The present invention relates to the preparation of a series of chiral DOTA, DO3A, DO2A, DO1A, cyclen and their metal complexes, which display properties superior to those of previous DOTA-based compounds, and hence are potentially valuable as a platform for diagnostic applications. The chiral DOTAs reveal a high abundance of twisted square antiprism (TSA) geometry favoring them to be used as potential MRI contrast agents, whereas their rapid labelling properties at mild conditions make them excellent candidates for use as radiometal chelators.

Abstract: Methods and compositions for treating, diagnosing and staging cancers, in particular overexpressing the Human Epidermal growth factor Receptor 2 protein (HER2+) given rise to in breast, gastric, gastroesophageal, ovarian, pancreatic cancer and brain tumors, which may be metastatic to the brain or other site. More specifically, the invention provides for Targeted Radionuclide Therapy (TRNT) with a compound of the invention having a peptide that targets the HER2+ cells, a second component for combining metals into complexes through a ring structure (DOTA), and a third radioisotope component, Lu-177 and Ga-68, in which embodiments further include a companion diagnostic, and in which embodiments further include anti-integrin precision medicines for cancers expressing ?v?3 and ?v?5 integrins, HER2+, vascular endothelial growth factor, vitronectin, fibronectin, tenascin, reelin, kindlin and talin.

Abstract: According to one implementation a central venous catheter is provided that includes an end emitting optical fiber that is configured to end emit bacterial disinfecting light to disinfect a conduit located inside the hub, the conduit connecting the working lumen of an infusion shaft with a working lumen of a main shaft.

Abstract: Compositions that are suitable for use as a disinfectant are disclosed. Methods of making and using compositions that are suitable for use as a disinfectant are also disclosed.

Abstract: A sterilization enclosure comprises one or more sensors for measuring characteristics within the container during a sterilization process, including one or more characteristics of sterilization agent(s), to determine whether instruments disposed within the container have been exposed to threshold process conditions to ensure a desired level of sterilization for those instruments.

Abstract: The invention provides an apparatus for treating surfaces of a container. The apparatus comprises an openable reaction chamber housing, an exhaust escapement and an electrode assembly. The electrode assembly comprises a probe assembly coupled with a power source, the probe assembly comprising an elongate wand body, and a helically configured primary electrode and a helically configured counter electrode disposed about an outer circumferential surface of the wand body in an alternating helical configuration. The elongate wand body has a fluid passageway defined therewithin, and one or more outlet openings that are formed on an outer circumferential surface of the wand body and that extend inward through said outer circumferential surface and upto the fluid passageway. One or both of the primary electrode and the counter electrode may be energizable by the power source.

Abstract: An excimer bulb assembly, with an excimer bulb, at least one integral captured reflector, and an integral filter such that the excimer bulb only emits substantial UV radiation between 200 nm and 230 nm, using a filter that passes light from about 200 nm to 234 nm (+/?2 nm).

Abstract: A water absorption treatment material absorbs a liquid containing a malodorous substance, and includes a first grain and a second grain. The first grain contains a metal having a deodorizing function. The second grain does not contain a metal having a deodorizing function.

Abstract: Aspects of the disclosure include an attachment for providing a scent to a container. In some aspects, a scent delivery system includes a bottle including a collar and a ledge structure each extending circumferentially outward; a scent ring loaded with a volatile chemical agent to emanate and generate a scent and including an interior protruding structure projecting from an interior wall of the ring, the scent ring configured to fasten around the neck of the bottle based on contact between the interior protruding structure and the ledge structure of the bottle; and a cap reversibly attachable to the bottle and including an interior rim structure that circumferentially projects from the interior of the cap, where the cap is structured to enclose the scent ring in a compartment formed between the collar and the interior rim structure when the cap is securely fastened to the bottle and trap the scent.

Abstract: An air flow system for reducing pathogens in a breathable airstream in an environment has a device having an airstream intake for receiving a volume of untreated air located in a first position, an airstream outlet for expelling a volume of treated air, the airstream outlet located in a second position extending above the first position, a flow path extending between the airstream intake and the airstream outlet, at least one of a UV generator and a UV-C emitter optically coupled to the flow path, a power source operably connected to the one of the at least one of the UV generator and the UV emitter, and a pressure generator fluidly connected to the airstream intake, the pressure generator configured to impart a flow from the airstream intake to the airstream outlet, wherein the pressure generator can be at least one of a force of flow from in line pressurized source or provided by a fan within the housing, and wherein a portion of the flow path includes a UV-C highly reflective surface.

Abstract: The present disclosure relates to a method for preparing an absorbable haemostatic composition for the body and the haemostatic composition prepared thereby, and the present disclosure is for providing a method for preparing an absorbable haemostatic composition for the body and the haemostatic composition prepared thereby, wherein the haemostatic composition can be used directly on the wound site when bleeding occurs in the surgical area such as surgical operation, trauma, etc. so that hemostasis can be effectively performed, the haemostatic composition can perform wound sealing, tissue repairing promotion, wound surface tissue protection, infection prevention, etc., the haemostatic composition is contained in haemostatic products such as gauze (cotton yarn), sponge, etc. to accelerate the hemostasis speed of the bleeding site and enable rapid hemostasis to be able to shorten the hemostasis time at the same time.

Abstract: The present invention relates to electrochemically initiated bioadhesive compositions comprising biocompatible polymers containing derivatives of diazonium, arylsulfonium, or diaryliodonium in general, and to their use in tissue fixation, in particular.

Abstract: A system related to the reparation of damaged veins along with the suspension of venous stasis progression by minimizing the leak reflux flow and the protection of the valve functions of the vena saphena magna, parva, perforator veins by means of exovascular or external filling agent injection in the treatment of venous stasis (which is also called varicose vein or varicose treatment).

Abstract: The present disclosure relates to a hydroxyapatite obtained from porous wood, having high compressive strength and dimensions suitable for clinical applications. The porous wood has a porosity of between about 60% and about 95%, said porosity being measured after subjecting the wood to a step of pyrolysis, and is selected from among rattan, pine, abachi, balsa, sipo, oak, rosewood, kempas and walnut wood. The hydroxyapatite may be substituted with one or more ions such as magnesium, strontium, silicon, titanium, carbonate, potassium, sodium, silver, gallium, copper, iron, zinc, manganese, europium, gadolinium. Also disclosed is a bone substitute comprising hydroxyapatite obtained from porous wood. The bone substitute is utilized for the substitution and regeneration of a bone or a bone portion, preferably for bones subjected to mechanical loads, such as long bones of the leg and arm, preferably the tibia, fibula, femur, humerus and radius.

Abstract: The invention provides a novel, versatile degradable hydrogel composition, and methods thereof, with precisely tunable stiffness, plasticity (e.g., degree of covalent vs. physical crosslinks) and predictive disintegration rates degradation, allowing controlled disintegration and release of therapeutic cells or pharmaceuticals and/or in vitro 3D cell expansion.

Abstract: Disclosed is a nano-layered dual hydroxide-biological factor combined system for promoting nerve regeneration to repair a spinal cord injury. The preparation method therefor comprises: 1) synthesizing a nano-layered dual hydroxide CL1; and 2) co-incubating 10 mg CL1 and 200-2000 ng of biological factors NT3, VEGF or bFGF in a low-speed shaker at 4° C. for 2 hours using an ion exchange method, centrifuging same and then obtaining the precipitate. Experiments on transection and resorption spinal cord injury models show that this combined system has a significant recovery effect on the behavior of model mice, can reconstruct the neural circuit of a damaged area over time and achieves an ideal repair effect with regard to a spinal cord injury.

Abstract: A method is used for preparing a product for use in repairing a lesion or defect at a tissue site in a human or animal patient body. The method includes obtaining tissue from a donor human or animal body and freezing the obtained tissue. The method further includes pulverizing the frozen tissue and suspending the pulverized tissue in a fluid. The method further includes homogenizing the tissue suspension and precipitating tissue particles from the homogenized tissue suspension. The method further includes re-suspending the precipitated tissue particles and lyophilizing the tissue re-suspension to provide the product to be used in repairing the lesion or defect.

Abstract: The present invention provides customized hybrid bone-implant grafts and a method of manufacture thereof.

Abstract: Collagen matrix granulate blend, and process for making and using a collagen matrix or granulate blend including collagen and particles of a biphasic calcium phosphate/hydroxyapatite (CAP/HAP) bone substitute material having a sintered CAP core and having its total external surface covered by at least one closed epitactically grown layer of nanocrystalline HAP deposited on the external surface of the sintered CAP core, whereby the epitactically grown nanocrystals have the same size and morphology as human bone mineral, wherein the closed epitactically grown layer of nanocrystalline HAP is transformed from the CAP on the external surface of the sintered CAP core has a non-homogeneous external surface comprising individual clusters of flat crystal platelets consisting of epitactically grown HAP nanocrystals and coarse areas between the individual clusters, whereby the percentage of the coarse areas between the individual clusters as measured by SEM is at least 20% of the total surface.

Abstract: An expandable medical balloon including an inner layer formed of a poly (ether-block-amide) copolymer and an outer layer formed of a polyamide, the expandable medical balloon having a burst strength of greater than 50,000 psi, and to methods of making and using the same.

Abstract: The invention is a wearable breast pump system including a housing shaped at least in part to fit inside a bra and a piezo air-pump. The piezo air-pump is fitted in the housing and forms part of a closed loop system that drives a separate, deformable diaphragm to generate negative air pressure. The diaphragm is removably mounted on a breast shield.

Abstract: The invention is a wearable breast pump system including a housing shaped at least in part to fit inside a bra and a piezo air-pump. The piezo air-pump is fitted in the housing and forms part of a closed loop system that drives a separate, deformable diaphragm to generate negative air pressure. The diaphragm is removably mounted on a breast shield.

Abstract: The present invention relates to an apparatus for degassing liquids comprising a degassing system, wherein the degassing system has a first degassing chamber, a second degassing chamber, a liquid store, a pump, and a supply line that connects the liquid store to the first degassing chamber; wherein the pump is connected to the first degassing chamber at the intake side and to the second degassing chamber at the pressure side; and wherein the degassing system furthermore has a return line that can be cut off and that connects the two degassing chambers to one another, and wherein the apparatus comprises a controller that is configured to operate the degassing system in a first operating mode and in a second operation mode; wherein the degassing system is connected in the first operation mode such that the pump conducts liquid away from the first degassing chamber and supplies it to a removal unit for degassed liquid; and wherein the degassing system is connected in the second operating mode such that liquid is

Abstract: Constraining adaptive optimizations of a state of an operation module of a medical device includes determining if a new state has at least one operational parameter that is outside a constraint that has been provided to the medical device in a non-repudiable manner, accepting the new state if no operational parameters are outside any of the constraints, and reverting the medical device to a previous valid state if at least one operational parameter is outside at least one of the constraints. The adaptive optimizations may be provided using artificial intelligence along with relevant inputs thereto. The medical device may be a dialysis system. Constraint data may be provided to the medical device along with a one-way hash value of the constraint data using, for example, a SHA 256 hash. The one-way hash value may be digitally signed using a private key that is part of a public/private key pair.

Abstract: Systems and methods are provided for performing a medical procedure within a patient's body that involves a thoracic duct including an ostium communicating with the patient's venous system. A distal end of a catheter is introduced through the patient's venous system into a body lumen adjacent the ostium of the thoracic duct. An expandable member on the distal end of the tubular member may be expanded adjacent the ostium, e.g., within the body lumen or the thoracic duct itself, and used to isolate the thoracic duct from the body lumen, whereupon a medical procedure may be performed via the thoracic duct. For example, lymphatic fluid may be removed from the thoracic duct through a lumen of the tubular member and/or one or more agents may be introduced into the thoracic duct through the tubular member.

Abstract: The invention is an innovative hybrid venous reservoir designed to receive and store blood during cardiopulmonary bypass (CPB), the hybrid venous reservoir consisting of an air purging chamber that limits air in the venous blood entering the air purging chamber from exiting the air purging chamber in combination with a compliant storage chamber with at least one pliable wall, the combination providing a large volume capacity while limiting the area of the blood-air interface to that of the air purging chamber.

Abstract: A medico-technical measuring device for measuring a property of a fluid, such as pressure for pressure measurement, includes a line extending along a central longitudinal axis to guide a fluid, such as blood, within a longitudinal cavity delimited by a wall. A sensor unit has a sensor and measures a property of the fluid guided in the longitudinal cavity. The line is provided with a radial cavity inserted in the wall in a radial direction, in which the sensor unit is at least partially arranged, and which is integrated in the wall such that the sensor is in communication with the fluid. In this way, a measuring device can be provided that allows simple handling—in particular, in combination with a comparatively precise measurement—especially, pressure measurement. The measuring device may be produced according to a method and the measuring device may be used in a measuring method.

Abstract: Methods and systems for priming a disposable fluid circuit for the processing of a biological fluid are disclosed. The methods and systems allow for variable and configurable priming of the flow path(s) leading to one or more biological fluid source containers.

Abstract: A filter assembly for use with a surgical suction tool for removing fluid and debris from a surgical site includes a conical filter element with a plurality of orifice arrays spaced along the length of the conical body with successively decreasing orifice diameters. The filter element includes an annular flange at the mouth of the filter element that is clamped between a container and a cap. The container includes conically tapered wall to define a radial space between the container and the filter element to permit fluid flow around the filter element and through the container to an outlet tube fitting. A cap covers the mouth of the container with a threaded interface defined between the cap and the container. The threaded interface includes a dual pitch triple lead thread with a coarse lead-in pitch and a fine trailing pitch.

Abstract: A wound packing material is provided, suitable for use in negative pressure wound therapy, including a body of a porous material, the body including frangible regions defining a plurality of portions, the frangible regions allowing the portions to be selectively removed from the body. Methods of manufacturing the wound packing material, and methods of its use are also provided.

Abstract: An apparatus and system for providing reduced pressure to a defect in a nerve is disclosed. The apparatus comprises a nerve conduit having a generally tubular shape that has walls including a luminal wall surrounding the tissue site to contain fluids within a luminal space between the tissue site to contain fluids within a luminal space between the tissue site and the luminal wall. The apparatus further comprises a manifold having a porous body and a connector for receiving reduced pressure, wherein the manifold is positioned within the luminal space adjacent the tissue site to distribute the reduced pressure to the defect. Additionally, a method for providing reduced pressure to a defect in a nerve is disclosed that includes implanting the nerve conduit and manifold at a site of damaged nerve tissue and applying a reduced pressure to the manifold thereby stimulating repair or regrowth of nerve tissue.

Abstract: This invention relates to the design of tissue covering elements for use in vacuum assisted tissue apposition systems, wherein the geometry of the covering elements favours the application of contractile forces over compressive or extensive forces at the tissue interface.

Abstract: In some embodiments, a negative pressure wound therapy system can detect and classify one or more operational conditions, including detection of a wound bleeding. The system can react to detection of blood by providing an indication, reducing the intensity or stopping therapy, releasing negative pressure, etc. In certain embodiments, the system can detect one or more additional operational conditions, such as change in vacuum pressure, gas leak rate change, exudate flow rate change, water flow rate change, presence of exudate, presence of water, etc. The system can detect and distinguish between different operational conditions and provide indication or take remedial action.

Abstract: The disclosed apparatus, system and method may include at least a surgical fluid container that includes a fluid reservoir capable of containing the surgical fluid and a gas pressure pocket applied to the surgical fluid therewithin; a first external port extending from outside the fluid reservoir into fluid communication with the surgical fluid within the fluid reservoir; and a second external port extending directly from outside the fluid reservoir into the gas pressure pocket.

Abstract: A closure container that can house a preset drug applicator in an easily accessible manner with tamper evidencing means. The closure container contains a plurality of dosing ribs and a retainer to retain the syringe in a preset dosage amount and preferably has a window to view the barrel of the syringe.

Abstract: A therapeutic substance delivery device includes a fluid path having a reservoir needle, a body needle, a body needle injection mechanism, and a pumping assembly (a) configured to pump the substance from the reservoir to the subject, (b) shaped to define a pump chamber, and (c) including a plunger disposed within the pump chamber. The plunger moves back and forth through a plurality of discrete motion phases. A first motion phase of the plunger actuates a first operation from a group of operations including (a) driving the reservoir needle to penetrate the reservoir, (b) advancing the body needle into the body of the subject, (c) withdrawing the substance from the reservoir, (d) pumping the substance into the subject, and (e) retracting the body needle. A second motion phase of the plunger actuates a second operation from the group of operations. Other applications are also described.

Abstract: A wearable infusion pump assembly includes a reusable housing assembly, and a disposable housing assembly including a reservoir for receiving an infusible fluid. The wearable infusion pump assembly also includes a releasable engagement assembly configured to allow the reusable housing assembly to releasably engage the disposable housing assembly. A switch assembly of the wearable infusion pump assembly is configured to effectuate a functionality of the infusion pump assembly.

Abstract: A multi-medicament infusion system (10) for preventing the mischanneling of medicaments may include an infusion pump (12), medicament reservoirs (16A,16B), a multi-channel lumen (18), and an infusion set (20). The medicament reservoirs may be sized and shaped differently such that the medicament reservoirs can only be inserted into the infusion pump in a unique configuration. The multi-channel lumen may include connectors that mate to corresponding connectors on the infusion pump and the infusion set only in a unique configuration. Because the various parts of the multi-infusion system may only be connected in the unique configuration, the expected medicaments may be administered appropriately and channeled to the correct infusion sites.